Safety and Metabolism of Long-Term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Healthy Overweight Adults

Objective

To evaluate the kinetics and dose-dependency of NR oral availability and safety in overweight, but otherwise healthy men and women.

Study Design

Randomized, double-blind, placebo-controlled, parallel assignment study in 140 overweight, but otherwise healthy men and women

Dose

100 mg, 300 mg, 1000 mg

Duration

8 weeks

Key Outcomes

  • NR supplementation significantly and dose-dependently increased whole blood NAD+ levels by 22%, 51%, and 142%, respectively, within two weeks. These levels were maintained throughout the remainder of the study.

Clinical, Pharmacokinetic/SafetyANAD Staff